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Angiotensin Production by the Heart
A Quantitative Study in Pigs With the Use of Radiolabeled
Angiotensin Infusions
Jorge P. van Kats, PhD; A.H. Jan Danser, PhD; Jan R. van Meegen, BSc;
Loes M.A. Sassen, MD, PhD; Pieter D. Verdouw, PhD; Maarten A.D.H. Schalekamp, MD, PhD
Background—Beneficial effects of ACE inhibitors on the heart may be mediated by decreased cardiac angiotensin II (Ang
II) production.
Methods and Results—To determine whether cardiac Ang I and Ang II are produced in situ or derived from the circulation,
we infused 125I-labeled Ang I or II into pigs (25 to 30 kg) and measured 125I-Ang I and II as well as endogenous Ang
I and II in cardiac tissue and blood plasma. In untreated pigs, the tissue Ang II concentration (per gram wet weight) in
different parts of the heart was 5 times the concentration (per milliliter) in plasma, and the tissue Ang I concentration
was 75% of the plasma Ang I concentration. Tissue 125I-Ang II during 125I-Ang II infusion was 75% of 125I-Ang II in
arterial plasma, whereas tissue 125I-Ang I during 125I-Ang I infusion was ,4% of 125I-Ang I in arterial plasma. After
treatment with the ACE inhibitor captopril (25 mg twice daily), Ang II fell in plasma but not in tissue, and Ang I and
renin rose both in plasma and tissue, whereas angiotensinogen did not change in plasma and fell in tissue. Tissue
125I-Ang II derived by conversion from arterially delivered 125I-Ang I fell from 23% to ,2% of 125I-Ang I in arterial
plasma.
Conclusions—Most of the cardiac Ang II appears to be produced at tissue sites by conversion of in situ–synthesized rather
than blood-derived Ang I. Our study also indicates that under certain experimental conditions, the heart can maintain
its Ang II production, whereas the production of circulating Ang II is effectively suppressed. (Circulation.
1998;98:73-81.)
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From experimental and clinical studies, there is evidenceto suggest that the long-term beneficial effects of ACE
inhibitor drugs on postinfarction cardiac failure and remod-
eling as well as on left ventricular hypertrophy are at least
partly independent of their systemic effect on blood pres-
sure.1,2 A reduction of Ang II production locally in the heart
may explain the blood pressure–independent effects of ACE
inhibition in cardiac patients.
Indeed, the heart contains all components required for Ang
I and Ang II production, ie, renin, angiotensinogen, and
ACE.3 Renin mRNA may be present in the heart in low
concentrations,4–7 but observations on the effect of bilateral
nephrectomy in pigs demonstrated that most, if not all, renin
in the heart is derived from the kidney, at least under normal
conditions.3 Angiotensinogen gene expression is also low in
the normal heart,7,8 and experiments using the isolated per-
fused rat heart seem to indicate that the heart produces little
Ang I and II when angiotensinogen is not added to the
perfusion fluid.9 In contrast, the synthesis of ACE in the
normal heart is an established fact.10–13 Angiotensinogen and
ACE gene expression may be upregulated under pathological
conditions.8,11,13
The study reported here focuses on the normal heart and is
carried out in pigs. It addresses the following questions: (1)
How much of the Ang I and II in cardiac tissue is derived
from the circulation? (2) How much of the cardiac Ang II is
synthesized locally by the conversion of blood-derived Ang I
and how much by the conversion of Ang I that is formed
locally in the heart? and (3) What is the effect of ACE
inhibitor treatment on cardiac angiotensin production?
Methods
Animals
All experiments were performed under the regulations of the Animal
Care Committee of the Erasmus University, Rotterdam, The Neth-
erlands, in accordance with the “Guiding Principles in the Care and
Use of Animals” as approved by the American Physiological
Society. Twenty-four female pigs (crossbred Yorkshire3Landrace,
Hedelse Varkens Combinatie, Hedel, The Netherlands) with a body
weight of 25 to 30 kg were included in the study. Ten animals were
pretreated with the ACE inhibitor captopril, 25 mg twice daily for 3
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days,14 for study of the effect of ACE inhibition on cardiac Ang I and
II production. The experiments were carried out 3 to 4 hours after the
last dose of captopril.
Instrumentation of the Animals
The animals were prepared for hemodynamic measurements, for
administration of anesthetic and 125I-labeled angiotensins, and for
blood and tissue sampling as described previously.3,14–16 After a
stabilization period of 30 to 45 minutes after completion of instru-
mentation, baseline measurements of systemic hemodynamic vari-
ables were made, and blood samples were collected for the determi-
nation of blood gases. The animals were then subjected to constant
infusions of either 125I-Ang I or 125I-Ang II.
Preparation of 125I-Labeled Angiotensins
[Ile5]-Ang-(1–10) decapeptide (Ang I) and [Ile5]-Ang-(1–8) oc-
tapeptide (Ang II) (Bachem) were used to prepare monoiodinated
125I-Ang I and II. The chloramine-T method was used for 125I-
labeling, and the radiolabeled peptides were purified as described
previously.17 The specific radioactivity of the 125I-Ang I and 125I-Ang
II preparations was '3.63106 cpm/pmol.
Infusion of 125I-Labeled Angiotensins
125I-Ang I or 125I-Ang II was administered via constant infusion into
the left cardiac ventricle for 15, 60, or 120 minutes. The infusion rate
was '43106 cpm/min for 125I-Ang I and '33106 cpm/min for
125I-Ang II. The levels of 125I-Ang I and 125I-Ang II reached their
steady-state maximum within 10 minutes in plasma14 and within 60
minutes in cardiac tissue.16 Seven untreated and 7 captopril-treated
pigs received a 125I-Ang I infusion for 15 minutes. Three untreated
and 3 captopril-treated pigs received a 125I-Ang I infusion for 60
minutes. Four untreated pigs received a 125I-Ang II infusion for 60
minutes. The number of 60-minute infusion experiments was kept at
a minimum to reduce the total quantity of radiolabeled angiotensin
required for the infusion. Measurements of the steady-state plasma
levels of 125I-Ang I and II were made in both the 15-minute and
60-minute experiments. Measurements of the steady-state tissue
levels of 125I-Ang I and II were made in the 60-minute infusion
experiments only.
Collection of Blood and Cardiac Tissue Samples
Blood samples (10 mL) were taken from the aorta and great cardiac
vein during infusion of 125I-Ang I or II to measure the plasma levels
of 125I-Ang I and II and endogenous Ang I and II. The blood was
rapidly drawn with a plastic syringe containing the following
inhibitors (0.5 mL inhibitor solution in 10 mL blood): 0.01 mmol/L
of the renin inhibitor remikiren (a kind gift of Dr W. Fischli,
Hoffmann-LaRoche, Basel, Switzerland), 6.25 mmol/L disodium
EDTA (Synthalyse), and 1.25 mmol/L 1,10-ortho-phenanthroline
(Merck) (final concentrations in blood). The blood was immediately
transferred into prechilled polystyrene tubes and centrifuged at
3000g for 10 minutes at 4°C. Plasma was stored at 270°C and
assayed within 3 days.
Aortic blood samples (5 mL) for measurements of renin and
angiotensinogen were collected in polystyrene tubes containing
disodium citrate (0.1 mL in 5 mL blood; final concentration,
13 mmol/L). The samples were centrifuged at 1000g for 10 minutes
at room temperature, and plasma was stored at 270°C.
Cardiac tissue was collected as follows. The heart was stopped by
fibrillation while the 125I-Ang I or II infusion was still running. The
heart was quickly removed from the body, and pieces weighing 1 to
2 g were quickly excised from the left and right atria and from the
left and right ventricular free wall. The tissue pieces were immedi-
ately transferred into liquid nitrogen. The tissue was frozen within 15
seconds after the heart had been stopped.
To study the ex vivo metabolism of endogenous angiotensins in
cardiac tissue, the remaining part of the left ventricular free wall was
kept at 37°C. Pieces of left ventricular tissue were then cut off and
frozen in liquid nitrogen at various time points after the heart had
been stopped. The frozen tissues were stored at 270°C and assayed
within 3 days.
Measurements of 125I-Labeled and Endogenous
Angiotensins in Cardiac Tissue and Blood Plasma
Frozen tissue samples were homogenized in 20 mL ice-cold 0.1
mol/L HCl/80% ethanol as previously described.3,16 The homogenate
was centrifuged at 20 000g for 25 minutes at 4°C. Ethanol in the
supernatant was evaporated under constant air flow, and the remain-
der of the supernatant was diluted in 20 mL 1% ortho-phosphoric
acid and centrifuged again at 20 000g. The supernatant was diluted
with an equal volume of 1% ortho-phosphoric acid and then
concentrated on Sep-Pak cartridges. Plasma was applied directly to
the Sep-Pak cartridges.
The preparation of the Sep-Pak extracts for HPLC separation of
the angiotensins and the HPLC procedure have been described
elsewhere.16 The concentrations of intact 125I-Ang I and 125I-Ang II
and the concentrations of intact Ang I and Ang II in the HPLC eluate
fractions were measured by gamma counting and radioimmunoassay,
respectively.17 Data were not corrected for losses that occurred
during extraction and separation. These losses were ,10% in plasma
and maximally 20% to 30% in tissue extracts.16 In some plasma
samples, the angiotensin levels were below the limit of detection.
These were taken to be equal to the lower limit of detection (1.0
fmol/mL for Ang I and 0.5 fmol/mL for Ang II) to allow calculation
of mean values.
Measurements of Renin and Angiotensinogen in
Cardiac Tissue and Blood Plasma
Frozen tissue samples were homogenized (1:3, weight:volume) in
0.01 mol/L phosphate buffer, pH 7.4, containing 0.15 mol/L NaCl as
previously described.3 Homogenates used for renin measurements
were pretreated with acid to remove angiotensinase activity.3 In
short, 1 mL of homogenate was dialyzed for 48 hours at 4°C against
0.05 mol/L glycine buffer, pH 3.3, containing 0.095 mol/L NaCl.3
This was followed by dialysis at 4°C for 24 hours against 0.1 mol/L
phosphate buffer, pH 7.4, containing 0.075 mol/L NaCl. The content
of the dialysis bags was then collected, and the volume was adjusted
to 1 mL with phosphate buffer.
The concentration of renin in acid-pretreated cardiac tissue extract
and in non–acid-pretreated plasma was determined by the enzyme-
kinetic assay, which measures the rate of Ang I generation at pH 7.4
during incubation at 37°C with a saturating amount of porcine renin
substrate, in the presence of inhibitors of angiotensinases, ACE, and
serine proteases.3 The Ang I–generating activity of cardiac tissue
extracts measured in the absence of the renin inhibitor remikiren
minus the Ang I–generating activity in the presence of remikiren
(final concentration, 1025 mol/L) was taken as a measure of the
concentration of renin. Inhibition of porcine renin is virtually
complete at this concentration of remikiren.3 Any remaining Ang
I–generating activity was assumed to be caused by enzymes other
than renin. Plasma had no Ang I–generating activity in the presence
of 1025 mol/L remikiren.
The concentration of angiotensinogen was determined in non–
acid-pretreated cardiac tissue extracts and plasma. It was measured
as the maximum quantity of Ang I that was generated during
incubation at 37°C with a high concentration of porcine kidney renin
in the presence of inhibitors of angiotensinases and ACE.3
Calculations
The possible sources of Ang I and II in cardiac tissue are shown in
Figure 1 and summarized in Table 1. The level of arterially delivered
Selected Abbreviations and Acronyms
Ang I 5 angiotensin I
Ang II 5 angiotensin II
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Ang II in cardiac tissue was calculated as
[Ang IItissue from Ang IIart]5R13[Ang IIart](1)
where [Ang IItissue from Ang IIart] is the Ang II concentration in
cardiac tissue (fmol/g) derived from arterially delivered Ang II, [Ang
IIart] is the Ang II concentration in aortic blood plasma (fmol/mL),
and R1 is given by
R15[125I-Ang IItissue]/[125I-Ang IIart](2)
where [125I-Ang IItissue] and [125I-Ang IIart] are the steady-state con-
centrations of 125I-Ang II in cardiac tissue (cpm/g) and aortic blood
plasma (cpm/mL), respectively, both during the constant infusion of
125I-Ang II.
The level of arterially delivered Ang I in cardiac tissue was
calculated as follows:
[Ang Itissue from Ang Iart]5R23[Ang Iart](3)
where [Ang Itissue from Ang Iart] is the Ang I concentration in cardiac
tissue (fmol/g) derived from arterially delivered Ang I, [Ang Iart] is
the Ang I concentration in aortic blood plasma (fmol/mL), and R2 is
given by
R25[125I-Ang Itissue]/[125I-Ang Iart](4)
where [125I-Ang Itissue] and [125I-Ang Iart] are the steady-state concen-
trations of 125I-Ang I in cardiac tissue (cpm/g) and aortic blood
plasma (cpm/mL), respectively, both during the constant infusion of
125I-Ang I.
The cardiac tissue level of Ang II that is derived by conversion
from arterially delivered Ang I was calculated as
[Ang IItissue from Ang Iart]5R33[Ang Iart](5)
where [Ang IItissue from Ang Iart] is the Ang II concentration in cardiac
tissue (fmol/g) derived from arterially delivered Ang I, [Ang Iart] is
the Ang I concentration in aortic blood plasma (fmol/mL), and R3 is
given by
R35([125I-Ang IItissue]/[125I-Ang Iart])2(R13[125I-Ang IIart]/(6)
[125I-Ang Iart])
where [125I-Ang IItissue] and [125I-Ang IIart] are the steady-state con-
centrations of 125I-Ang II in cardiac tissue (cpm/g) and aortic blood
plasma (cpm/mL), respectively, and [125I-Ang Iart] is the steady-state
concentration of 125I-Ang I in aortic blood plasma (cpm/mL), all
during the constant infusion of 125I-Ang I.
Some of the Ang I and II in cardiac tissue may originate from Ang
I and II that is generated by the action of circulating renin with
circulating angiotensinogen during the passage of blood from the
arterial to the venous end of the coronary circulation. The Ang
I–generating capacity of blood plasma was calculated as
AGCplasma5[Ren]3[Aog]/(Km1[Aog])(7)
where AGCplasma is the Ang I–generating capacity of plasma (fmol
Ang I z mL21 z min21), [Ren] is the renin concentration of plasma
(fmol Ang I z mL21 z min21), [Aog] is the angiotensinogen concen-
tration of plasma (pmol/mL), and Km is the Michaelis-Menten
constant for the reaction of porcine renin with porcine angioten-
sinogen, which equals 420 pmol/mL.9 The cardiac tissue level of
Ang I that originates from the Ang I–generating capacity of plasma
was calculated as
[Ang Itissue from AGCplasma]5R2/R923AGCplasma3t(8)
where [Ang Itissue from AGCplasma] is the Ang I concentration in
cardiac tissue (fmol/g) originating from the Ang I–generating
capacity of plasma, t is the coronary blood transit time, which equals
0.1 minute,18 R2 is given by Equation 4, and R92 is given by
R925[125I-Ang Iven]/[125I-Ang Iart](9)
where [125I-Ang Iven] and [125I-Ang Iart] are the steady-state concen-
trations (cpm/mL) of 125I-Ang I in coronary venous and aortic blood
plasma, respectively, both during the constant infusion of 125I-Ang I.
In Equation 8, it is assumed that the Ang I in tissue originating from
the Ang I–generating capacity of blood plasma is not subject to
conversion and degradation by the vascular endothelium. If, how-
ever, this Ang I is exposed to the endothelial peptidases, in the same
way as arterially delivered Ang I, the factor R2/R92 in Equation 8 has
to be substituted by R2. In reality, the fractional conversion and
degradation of plasma Ang I generated in the coronary circulation
are probably lower than the fractional conversion and degradation of
arterially delivered Ang I. If the R2-to-R92 ratio is taken, Equation 8
gives a maximum value of [Ang Itissue from AGCplasma].
The cardiac tissue level of Ang II that originates from the Ang
I–generating capacity of plasma was calculated as
[Ang IItissue from AGCplasma]5(R933R2/R92)3AGCplasma3t(10)
where R93 is given by
R935([125I-Ang IIven]/[125I-Ang Iart])(11)
2(R913[125I-Ang IIart]/[125I-Ang Iart])
In Equation 11, [125I-Ang IIven] and [125I-Ang IIart] are the steady-state
concentrations (cpm/mL) of 125I-Ang II in coronary venous and aortic
Figure 1. Schematic of sources of Ang I and II in cardiac
tissue and coronary venous (ven) plasma. Ang I–to–II
conversion in plasma and conversion on endothelial sur-
face are indicated separately. Aog indicates angioten-
sinogen; art, arterial.
TABLE 1. Sources of Ang I and II in Cardiac Tissue
Ang I Ang II
Ang I in coronary artery Ang II in coronary artery
Ang I produced by the fluid-phase
reaction of renin with
angiotensinogen in the coronary
circulation
Ang I synthesized in situ in
cardiac tissue
Ang I in coronary artery
Ang I produced by the fluid-phase
reaction of renin with
angiotensinogen in the coronary
circulation
Ang I synthesized in situ in cardiac
tissue
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blood plasma, respectively, and [125I-Ang Iart] is the steady-state
concentration (cpm/mL) of 125I-Ang I in aortic blood plasma, all
during the constant infusion of 125I-Ang I. R91 is given by
R915[125I-Ang IIven]/[125I-Ang IIart](12)
where [125I-Ang IIven] and [125I-Ang IIart] are the steady-state concen-
trations (cpm/mL) of 125I-Ang II in coronary venous and aortic blood
plasma, respectively, both during the constant infusion of 125I-Ang II.
Equation 10 gives a maximum value of [Ang IItissue from AGCplasma],
for the same reasons as for Equation 8.
Statistical Analysis
Data are expressed as mean6SD except when indicated otherwise.
Differences in plasma levels of renin-angiotensin system compo-
nents between untreated and captopril-treated pigs were tested by
Student’s t test. Differences in cardiac tissue levels of renin-angio-
tensin system components between untreated and captopril-treated
pigs were tested by MANOVA. Statistical significance was accepted
for P,0.05.
Results
Hemodynamic Effects of 125I-Labeled Angiotensins
Baseline heart rate, cardiac output, and mean arterial pressure
did not differ between untreated and captopril-treated pigs
(Table 2). Infusions of either 125I-Ang I or 125I-Ang II did not
affect any of these parameters (data not shown), which is in
agreement with previous studies.14,16,17
125I-Labeled Angiotensins in Cardiac Tissue and
Blood Plasma
The steady-state levels of 125I-Ang I and II in aortic plasma
during constant infusion of 125I-Ang I or II are shown in Table
2. 125I-Ang II in plasma was lower and 125I-Ang I was higher
in the captopril-treated pigs than in the controls. The ratio of
125I-Ang II to I in plasma, which is a measure of the degree of
ACE inhibition, fell from 0.71 to 0.11 after captopril.
Table 3 gives the cardiac tissue and coronary venous
plasma concentrations of Ang I and II derived from arterially
delivered Ang I or II, expressed as a fraction, R, of the Ang
I or II concentration in arterial blood plasma. The R values
were calculated from the steady-state 125I-Ang I and II levels
in cardiac tissue (cpm/g), coronary venous plasma (cpm/mL),
and aortic plasma (cpm/mL) during 125I-Ang I or II infusions.
After captopril treatment, the coronary venous plasma
concentration of 125I-Ang II that is derived by conversion
from arterially delivered 125I-Ang I fell from 32% to 4% of the
125I-Ang I concentration in arterial plasma. This demonstrates
effective ACE inhibition in the coronary vascular bed.
TABLE 2. Baseline Hemodynamic Parameters and Steady-State Arterial Plasma Levels of 125I-Labeled Ang I and II During Infusion of
125I-Ang I or II in Untreated and Captopril-Treated Pigs
Treatment Group
Mean Arterial
Pressure,
mm Hg
Heart Rate,
bpm
Cardiac Output,
L/min
125I-Ang I Concentration,
cpm/mL
125I-Ang II Concentration,
cpm/mL Ratio of 125I-Ang II to I
125I-Ang I infusion
Control (n510) 86612 123612 2.560.5 13506380 9606390 0.7160.22
Captopril (n510) 8564 112615 2.760.6 19606720* 2406210* 0.1160.04*
125I-Ang II infusion
Control (n54) 78613 110615 2.360.7 . . . 19606530 . . .
The plasma levels of 125I-Ang I and II presented here were measured in blood samples taken from the aorta at the end of a 10-minute infusion period. Data are
mean6SD.
*P,0.01 for difference from results in control animals receiving 125I-Ang I infusion (unpaired Student’s t test).
TABLE 3. Cardiac Tissue and Coronary Venous Plasma Concentrations of Ang I and II
Derived From Arterially Delivered Ang I or II, Expressed as a Fraction, R, of the Ang I or II
Concentration in Arterial Plasma
Cardiac Tissue Coronary Venous Plasma
R1 R2 R3 R91 R92 R93
Control 0.75 (0.71–0.81) ,0.04 0.23 (0.12–0.37) 0.5260.17 0.4160.14 0.3260.22
(n53) (n53) (n53) (n54) (n510) (n510)
Captopril ND ,0.02 ,0.02 ND 0.5860.15* 0.0460.05*
(n53) (n53) (n510) (n510)
ND indicates not done. R1 through R3 are given by Equations 2, 4, and 6 and R91 through R93 are given by Equations
9, 11, and 12. The R and R9 values were calculated from the 125I-Ang I and II levels in cardiac left ventricular tissue,
coronary venous blood plasma, and aortic blood plasma during 125I-Ang I or II infusions. R1 and R91 represent the
concentrations of Ang II in cardiac left ventricular tissue and coronary venous plasma, respectively, derived from
arterially delivered Ang II and expressed as a fraction of the concentration of Ang II in aortic plasma. R2 and R92
represent the concentrations of Ang I in cardiac left ventricular tissue and coronary venous plasma, respectively,
derived from arterially delivered Ang I and expressed as a fraction of the concentration of Ang I in aortic plasma. R3
and R93 represent the concentrations of Ang II in cardiac left ventricular tissue and coronary venous plasma,
respectively, derived by conversion from arterially delivered Ang I and expressed as a fraction of the concentration
of Ang I in aortic plasma. Data are mean6SD or means and ranges.
*P,0.01 for difference from results in control animals (unpaired Student’s t test).
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In the control group, the 125I-Ang II concentration in
cardiac tissue during 125I-Ang II infusion was 75% of its
concentration in arterial plasma. In contrast, the cardiac tissue
concentration of 125I-Ang I during 125I-Ang I infusion was
,4% of its concentration in arterial plasma. The tissue
concentration of 125I-Ang II that was derived by conversion
from arterially delivered 125I-Ang I was 23% of the 125I-Ang I
concentration in arterial plasma. This percentage was much
lower, ,2%, in the captopril-treated group, which is again an
indication of effective blockade of conversion of Ang I to II.
Endogenous Angiotensins in Cardiac Tissue
and Plasma
The levels of endogenous Ang I and II in cardiac tissue and
blood plasma are shown in Figures 2 and 3. Plasma Ang I and
II in untreated pigs were within the normal range.19 No
significant differences were observed between aortic and
coronary venous plasma.
The tissue levels in the various parts of the heart were not
significantly different in either the captopril-treated or un-
treated pigs, but there were marked differences between
tissue and plasma. The tissue concentration of Ang II in the
untreated group was '5 times the plasma concentration of
Ang II. In addition, the tissue concentration of Ang II was .5
times the concentration of Ang I, whereas in plasma, Ang II
was lower than Ang I.
Ang I rose after captopril both in tissue and in plasma. Ang
II in tissue did not change after captopril, whereas in plasma,
Ang II fell to values close to the detection limit of the assay.
Routinely, as described in the “Methods” section, Ang I
and II were measured in cardiac tissue that was frozen within
15 seconds after the heart had been stopped and removed
from the body. When cardiac tissue was kept at 37°C for 1
hour after the heart had been removed from the body, the
tissue levels of Ang I and II were virtually constant during
this period, and they were similar to the routinely measured
levels (Figure 4).
Renin and Angiotensinogen in Cardiac Tissue and
Blood Plasma
The tissue levels of renin and angiotensinogen in the various
parts of the heart were not significantly different in either the
captopril-treated animals or in controls (Table 4). The tissue
concentration of renin (expressed per gram tissue) was
similar to the plasma concentration (expressed per milliliter).
This suggests that the presence of renin in tissue is not
restricted to the extracellular fluid compartment. In contrast,
the tissue concentration of angiotensinogen (expressed per
gram tissue) was 10% to 30% of the plasma concentration
(expressed per milliliter).
As expected, the plasma and tissue levels of renin were
higher in the captopril group than in controls. The plasma
levels of angiotensinogen were not different between the two
Figure 2. Ang I and II levels in cardiac tissue of
untreated (open bars, n510) and captopril-treated
(hatched bars, n510) pigs. Values are geometric
means and SD. Ang I levels in the two groups of ani-
mals are significantly different (P,0.01, MANOVA).
Figure 3. Ang I and II levels in blood plasma of untreated (open
bars, n514) and captopril-treated (hatched bars, n510) pigs.
Values are geometric means and SD. *P,0.05, **P,0.01 for dif-
ference from control animals (unpaired Student’s t test).
Figure 4. Ex vivo changes of Ang I (F) and II (E) at 37°C in
cardiac tissue (left ventricular free wall) of untreated (top) and
captopril-treated (bottom) pigs. Values (means and SD of 4
experiments) are expressed as percentage of level in tissue
samples frozen within 15 seconds after removal of heart
from body.
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groups, but the tissue levels of angiotensinogen were lower in
the captopril group, which is an indication of increased
substrate consumption due to elevated renin.
Contributions of Blood-Derived Angiotensins to
the Angiotensin Levels in Cardiac Tissue
Figures 5 and 6 show the results for Ang I and II in left
ventricular free wall tissue both in the captopril-treated pigs
and in controls. It appears that .90% of the Ang I in tissue
is synthesized in the tissue itself and is not derived from the
circulation. Most of the Ang II in tissue is also synthesized in
the tissue, and its source is Ang I synthesized in situ rather
than Ang I from the circulation. The contribution of Ang I
from the circulation to the cardiac tissue level of Ang II was
small in the control group and fell to nearly zero after
captopril because of the blockade of Ang I–to–II conversion.
Discussion
In the present study, 125I-Ang I and 125I-Ang II were infused
into the left cardiac ventricle to determine how much of the
Ang I and II in cardiac tissue is derived from the circulation
and how much is generated in situ. The results indicate that
most, if not all, Ang I we measured in cardiac tissue was
synthesized in situ and that most of the cardiac Ang II was
produced by the conversion of this in situ–synthesized Ang I.
We used tracer doses of 125I-Ang II to minimize the chance
of a physiological effect. No hemodynamic response was
detectable.14,16 The steady-state plasma level of 125I-Ang II
was '2000 cpm/mL (Table 2), which corresponded with a
plasma concentration of '0.55 fmol/mL. The plasma level of
endogenous Ang II was 2 fmol/mL. Thus, the 125I-Ang II
infusion caused an increase of the plasma Ang II concentra-
tion by only 25%. With the 125I-Ang I infusions, the increase
of plasma Ang II was even less. An important effect on AT1
receptor density is therefore unlikely.
In our calculations, it was assumed that the fate of the
radiolabeled angiotensins in cardiac tissue and the coronary
circulation is comparable to that of arterially delivered
nonlabeled angiotensins. Previous studies in pigs14 and hu-
mans20 demonstrated that the 125I-Ang I–to–II conversion rate,
both in vitro and in vivo, is about two times the Ang I–to–II
conversion rate and that the rates at which 125I-Ang I and Ang
I are degraded into peptides other than 125I-Ang II and Ang II
are not different. The 125I-Ang II and Ang II degradation rates
are also not different.20 The fact that the 125I-Ang I–to–II
Figure 5. Contributions of various sources of Ang I to cardiac
tissue (left ventricular free wall) level of this peptide in untreated
and captopril-treated pigs. Values (means and ranges of 3
experiments) are percentage of total tissue level of Ang I. A, Ar-
terially delivered Ang I; B, Ang I produced by Ang I–generating
capacity of plasma in coronary circulation; C, Ang I synthesized
in situ in cardiac tissue.
TABLE 4. Concentrations of Renin, Angiotensinogen, and the Ratio of Ang II to I
Concentration in Cardiac Tissue and Arterial Blood Plasma in Untreated (n514) and
Captopril-Treated (n510) Pigs
Treatment Group Aortic Plasma Left Atrium Right Atrium Left Ventricle Right Ventricle
Renin, fmol Ang I z
mL21 z min21 or fmol
Ang I z g21 z min21
Control 26634 38625 40617 31616 25613
Captopril 78639* 114661‡ 101643‡ 107652‡ 85639‡
Angiotensinogen, pmol/mL
or pmol/g
Control 340672 62647 47617 98639 73645
Captopril 3396103 41625‡ 3066‡ 60642‡ 44627‡
Ang I–generating
capacity, fmol Ang I z
min21 z mL
Control 12616
Captopril 29614*
Ratio of Ang II to I
Control 0.6760.35 15.966.4 8.465.0 5.262.2 9.469.3
Captopril 0.0660.07† 6.265.2‡ 2.362.1‡ 2.861.8‡ 5.067.7‡
g indicates gram tissue wet weight. Data are mean6SD.
*P,0.05, †P,0.01 for difference from control animals (unpaired Student’s t test).
‡Tissue concentrations of renin and angiotensinogen and the ratio of Ang II to I tissue concentration in the two
groups of animals are significantly different (P,0.01, MANOVA).
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conversion rate is somewhat higher than the Ang I–to–II
conversion rate may have led us to overestimate the amount
of Ang II in cardiac tissue that is derived from Ang I in the
circulation. Therefore, this does not invalidate our conclusion
that most of the Ang II in cardiac tissue is generated from in
situ–synthesized rather than blood-derived Ang I.
An important methodological aspect of this study relates to
the question of whether the radiolabeled and endogenous
angiotensin levels we measured in cardiac tissue are repre-
sentative of the levels in vivo. The finding that the ex vivo
cardiac tissue levels of Ang I and II remained practically
constant at 37°C lends support to the assumption that the
measured levels are close to the in vivo levels. The ex vivo
half life of 125I-Ang II in cardiac tissue at 37°C is 30 to 40
minutes.16 Thus, the 125I-Ang II level we measured in cardiac
tissue that was frozen within 15 seconds after the 125I-Ang I
and II infusions had been stopped and the heart had been
removed from the body is probably also close to the 125I-Ang
II level in vivo. Ex vivo production of Ang II may explain
why endogenous cardiac Ang II, as opposed to radiolabeled
Ang II, remained constant when cardiac tissue was kept at
37°C.
The tissue level of 125I-Ang I was too low to determine the
ex vivo half life of 125I-Ang I. The 125I-Ang I level we
measured in cardiac tissue that was frozen within 15 seconds
after 125I-Ang I infusion had been stopped and the heart had
been removed from the body was ,4% of the plasma level in
the aorta. The fact that the tissue level of 125I-Ang I is
probably only a small fraction of the level in arterial plasma
in vivo as well is supported by the following considerations:
(1) the rate of Ang I production in tissue ex vivo is probably
not higher than in vivo, (2) the tissue concentration of Ang I
we measured is close to the level in vivo, and (3) Ang I
delivery by the aorta contributes to the tissue level of Ang I in
vivo but not ex vivo. The third consideration implies that if
the two other considerations are correct, arterially delivered
Ang I will contribute little to its level in tissue.
Our finding that the tissue-to-plasma ratio of 125I-Ang II
during 125I-Ang II infusion was much higher than the tissue-
to-plasma ratio of 125I-Ang I during 125I-Ang I infusion may
suggest that the two peptides are located in different tissue
compartments. An earlier study16 in which we infused 125I-
Ang I and 125I-Ang II into the left cardiac ventricle of pigs
provided evidence that most of the 125I-Ang II in cardiac
tissue had been accumulated by the cells via an angiotensin
AT1 type receptor–mediated process. 125I-Ang I does not bind
to the AT1 receptor and does not enter the cells via this
receptor, so the location of 125I-Ang I in the tissue may be
restricted to the extracellular compartment.
Studies with a modified rat Langendorff heart model,
which allowed us to collect interstitial fluid transudate sepa-
rately from the coronary effluent, showed that the Ang I
concentration in interstitial fluid during perfusion of the heart
with Ang I was only 10% to 20% of the Ang I concentration
of the inflowing perfusion fluid.9 When this also holds for the
125I-Ang I we infused into the pigs in the present experiments
and when, as discussed above, 125I-Ang I in cardiac tissue is
restricted to the extracellular compartment, it is easy to
understand why the cardiac tissue level of 125I-Ang I we
measured in the present study was so low.
The conclusion that 125I-Ang I and therefore also the
arterially delivered nonlabeled Ang I are localized in the
extracellular compartment and that 125I-Ang II and the arteri-
ally delivered nonlabeled Ang II are accumulated in the cells
via binding to AT1 receptors may also hold for Ang I that is
synthesized at tissue sites and for Ang II that originates from
this in situ–synthesized Ang I. Further studies are needed to
settle this issue.
Our observations in nephrectomized pigs demonstrated
that at least in the healthy heart, most if not all of the cardiac
Ang I and II is generated by blood-derived renin.3 The
captopril-induced parallel increments in plasma renin and
cardiac Ang I, as shown in the present study, support the
assumption that also during captopril treatment, the cardiac
production of Ang I and II depends on blood-derived renin.
This, together with the evidence that most of the Ang I and II
in cardiac tissue does not originate from the circulation but
rather from local production, confirms the concept, already
proposed by Loudon et al21 .10 years ago, that one of the
principal functions of renin secretion by the kidney is to
ensure the delivery of this enzyme to vascular tissues for the
production of angiotensins in these tissues.
Recent evidence seems to indicate that binding sites for
renin are present in the cell membrane fractions of rat cells
from different organs, including the heart, blood vessels, and
kidney.22–25 Also in the porcine heart, renin was found to be
membrane bound.3 Cell membrane binding would be a
mechanism by which renin from the circulation is accumu-
lated at certain tissue sites, resulting in higher renin concen-
trations at these sites than in the circulating blood.
In view of the possibility that the beneficial effects of ACE
inhibitor drugs on cardiac function and structure depend on
their effect on cardiac Ang II production rather than on a
decrease in circulating Ang II, it is of interest to note that in
Figure 6. Contributions of various sources of Ang II to
cardiac tissue (left ventricular free wall) level of this pep-
tide in untreated and captopril-treated pigs. Values
(means and ranges of 3 experiments) are percentage of
total tissue level of Ang II. A, Arterially delivered Ang II; B,
Ang II derived by conversion from arterially delivered Ang
I; C, Ang II derived by conversion from Ang I produced
by Ang I–generating capacity of plasma in coronary cir-
culation; and D, Ang II derived by conversion from Ang I
that is synthesized in situ in cardiac tissue.
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our experiments, the cardiac tissue level of Ang II, as opposed
to its level in plasma, did not fall after ACE inhibition by
captopril. Other investigators, using various ACE inhibitor
drugs in rats, observed a reduction in cardiac Ang II.26–29
However, these studies also indicated differences between the
effects of ACE inhibitor treatment on Ang II production in
the circulation and in tissues. Perindopril, for instance, caused
a dose-dependent decrease in the Ang II–to–I concentration
ratio in plasma, but at each dose, the effect on this ratio was
greater in plasma than in cardiac tissue.28 Quinapril lowered
cardiac Ang II in rats with volume overload–induced cardiac
hypertrophy but not in normal rats, whereas plasma Ang II
was suppressed in both groups.29 Results may therefore differ
depending on the type and dose of ACE inhibitor and on
whether the animals are studied under normal or pathological
conditions.
In our experiments, the compensatory increase in Ang I
production in the heart might have overcome the blockade
of ACE. The increased tissue concentration of Ang I and
the decreased tissue concentration of angiotensinogen, as
observed in our study, are indications that the cardiac
production of Ang I was indeed increased. It is also
possible that captopril does not reach some of the tissue
sites of Ang II production. Furthermore, enzymes other
than ACE may be involved in the Ang I–to–II conversion
in cardiac tissue, eg, chymase.30 However, the role of
enzymes other than ACE in cardiac Ang II production
remains questionable.31,32
The results of the present study, together with our recent
observations on the AT1 receptor–mediated cardiac uptake of
Ang II and its long intracellular half life,16 also raise the
interesting possibility that AT1 receptor antagonism and ACE
inhibition have different effects on the distribution of locally
produced Ang II over the intracellular and extracellular
cardiac tissue compartments. Both treatment modalities tend
to reduce the number of AT1 receptors that are occupied with
Ang II, and in both cases this is counteracted by a compen-
satory response of stimulated renin and Ang I production.
However, AT1 receptor–mediated endocytosis of Ang II
protects this peptide against the enzymes that degrade extra-
cellular Ang II, so that during AT1 receptor blockade a larger
proportion of tissue Ang II is exposed to these enzymes. This
is also supported by the finding that the ratio of cardiac Ang
II to I concentration was decreased in rats by treatment with
the AT1 receptor antagonist losartan, which had no effect on
cardiac ACE.33 It is therefore possible that, for a given
increment of Ang I, the tissue level of Ang II is more reduced
by AT1 receptor antagonist drugs than by ACE inhibitors.
This may have clinical consequences, in light of growing
evidence that the physiological responses to Ang II not only
are mediated by signal transduction from cell surface–bound
Ang II receptors but that intracellular Ang II also contributes
to these responses.34–36
Further studies of the effects of ACE inhibitors, AT1
receptor antagonists, and renin inhibitors on the local produc-
tion of Ang I and II in cardiac and vascular tissues along the
lines of the present study will clarify the pathophysiological
significance of Ang II production in these tissues and may
help to better define the place of these drugs in the manage-
ment of heart failure and hypertension.
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